FMR LLC cut its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 97.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 117,748 shares of the company's stock after selling 4,596,424 shares during the period. FMR LLC owned approximately 0.12% of Acelyrin worth $580,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in SLRN. Principal Financial Group Inc. purchased a new stake in shares of Acelyrin during the second quarter worth approximately $49,000. SG Americas Securities LLC acquired a new position in Acelyrin in the 2nd quarter valued at $51,000. Nisa Investment Advisors LLC raised its position in Acelyrin by 58,570.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company's stock worth $62,000 after buying an additional 14,057 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Acelyrin in the 3rd quarter worth $77,000. Finally, US Bancorp DE boosted its holdings in shares of Acelyrin by 77.1% in the third quarter. US Bancorp DE now owns 16,854 shares of the company's stock valued at $83,000 after acquiring an additional 7,336 shares in the last quarter. 87.31% of the stock is owned by institutional investors and hedge funds.
Acelyrin Trading Down 1.5 %
Shares of SLRN traded down $0.05 during trading hours on Thursday, reaching $3.22. The company had a trading volume of 761,783 shares, compared to its average volume of 999,853. Acelyrin, Inc. has a 12-month low of $3.11 and a 12-month high of $8.89. The firm has a 50 day simple moving average of $5.05 and a 200-day simple moving average of $4.97. The company has a market capitalization of $323.05 million, a price-to-earnings ratio of -1.31 and a beta of 1.61.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on SLRN. Wells Fargo & Company cut their price target on shares of Acelyrin from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. HC Wainwright reissued a "neutral" rating and set a $8.00 target price on shares of Acelyrin in a research note on Wednesday, December 11th.
Check Out Our Latest Analysis on SLRN
Acelyrin Profile
(
Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Read More
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
